Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FlutiForm versus fluticasone plus formoterol in adults with severe persistent reversible asthma
2007-001633-34Phase 3Completed
- Sponsor
- Mundipharma
- Start
- May 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fluticasone propionate + formoterol, fluticasone propionate and formoterol in asthma (4 arms), sponsored by Mundipharma. Primary endpoints: Mean change in pre-morning dose FEV1 from baseline to end of 8-week treatment, Mean change from baseline pre-morning dose FEV1 to 2-hour post-morning dose FEV1 at week 8 and 1 more. Started May 2008; status: completed.
02
Drugs
fluticasone propionate + formoterolfluticasone propionateformoterol
03
Conditions
asthma
Beyond the preview
Go deeper on 2007-001633-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001633-34.